Bextra Physician Letter Could Be Additional Boon For OTC NSAIDs
This article was originally published in The Tan Sheet
Executive Summary
Pfizer will conduct further studies on the long-term cardiovascular safety profile ofBextra (valdecoxib), following results from two studies in surgical settings that showed an increase in cardiovascular events in patients taking the COX-2 arthritis treatment
You may also be interested in...
Wyeth, McNeil Strike Swiftly With Ads After Vioxx Recall
Wyeth Consumer Health and McNeil are capitalizing on concerns generated by Merck's recall of its prescription pain reliever Vioxx with ads for Advil (ibuprofen) and Tylenol (acetaminophen)
Reversal Of Fortune? Vioxx Recall Presents Opportunity For NSAID Makers
OTC NSAID manufacturers could be the indirect beneficiaries of Merck's decision to initiate a worldwide recall of its COX-2 inhibitor Vioxx (rofecoxib)
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC